On October 1, 2011, BioConnection welcomed Joe Bender as their new Business Development Officer and Robert de Boer as their Program Manager.

Focus Reports published an interview with BioConnection's CEO Alexander Willemse. Read the full interview online

On January 16 2011, the 'Life Sciences, Biotechnology and Food Security News' was distributed with The Sunday Times. BioConnection was interviewed on their opinion of the future of (bio) manufacturing and development. Read the full article online at www.biotechandfoodsecurity.com

Oss, The Netherlands, April 14th, 2011

BioConnection today announced that they are selected by Biokine Therapeutics as their development and cGMP manufacturer partner for Biokines lead product BKT140. Biokine, based in Rehovot, Israel, targets the CXCR4 Chemokine Receptor which is a key molecule involved in the regulation of different cancer diseases. CXCR4 is known also to be involved in the emerging field of stem cell biology and tissue regeneration. 


Oss, The Netherlands, November 12, 2010

BioConnection BV today announced the successful completion of a feasibility study for InnoCore Technologies and Nanomi, regarding the cGMP manufacturing of their advanced controlled release microsphere formulationsbased on the SynBiosysÒ biodegradable polymeric drug delivery system and Monosphere™ monodisperse microsphere manufacturing technology.

Fewer than one in a hundred ideas makes it to be a registered medicine. Most potential victims fall by the wayside during the test phase, for example during clinical trials and/or during scaling up for industrial production. Read the full article as PDF (English)
Minder dan één op de honderd ideeën haalt het tot een geregistreerd medicijn. De meeste potentiële slachtoffers vallen in de testfase tijdens bijvoorbeeld het klinisch onderzoek en/of bij het opschalen naar industriële productie. Lees hier het volledige artikel in PDF (nederlands)

BioConnection has been working for three years already to achieve the best results for young, innovative biopharmaceutical R&D companies. Our company vision turns out to be spot on. After all, our state-of-the-art facilities and comprehensive services are becoming increasingly well-known and satisfy a growing need.

By gmiller

Several contract manufacturing announcements indicate that production demand is on the rise.
Formulation developer CoreRx has announced plans to expand in the U.S. and Schering-Plough has opened a facility in The Netherlands.

Schering-Plough has opened a new pharmaceutical manufacturing facility in Oss, the Netherlands, to help meet demand for the drugmakers' injectable drugs and hormonal products and boost its capacity to make biologics.

BioConnection is alweer drie jaar onderweg om voor jonge, innovatieve biofarmaceutische R&D bedrijven de beste resultaten te bereiken. Onze bedrijfsvisie blijkt een schot in de roos. Immers onze state of the art faciliteiten en uitgebreide services worden steeds bekender en voldoen in een groeiende behoefte.

You can read the entire interview (in dutch) by clicking on the link below
Interview (pdf 985kb)

On october 13, 2008, we welcomed Sjaak Stevens as the new Business Develop Manager of BioConnection.